Treating alcoholrelated. depression. James Foulds Senior Lecturer National Addiction Centre Christchurch, NZ

Similar documents
TITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness

Pharmacotherapy for Alcohol Dependence

Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol

Depression & Alcohol

Evidence Based Medicine

Doug Sellman Professor of Psychiatry & Addiction Medicine National Addiction Centre University of Otago, Christchurch

Results. NeuRA Treatments for dual diagnosis August 2016

IDDT Fidelity Action Planning Guidelines

Mood Disorders and Addictions: A shared biology?

Te Rau Hinengaro: The New Zealand Mental Health Survey

Conor K Farren. St Patricks University Hospital Trinity College Dublin Ireland

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care

Great Debates Evidence-Based Practice: Specific Methods and/or Therapeutic Relationship?

BEST in MH clinical question-answering service

REVIEW ARTICLE MANAGEMENT OF PATIENTS WITH MOOD DISORDERS AND COMORBID SUDS

60 minutes Give examples of SMARTs that are completed or in the field o ASD, child ADHD, women who are pregnant and abuse substances, adult alcohol

Management of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013

ROYAL COLLEGE OF PSYCHIATRISTS RAPID EVIDENCE REVIEW OF EVIDENCE-BASED TREATMENT FOR GAMBLING DISORDER IN BRITAIN

Alcohol And Mood Disorders. L.E. Smit, MD, FRCPC. Objectives. February 8, 2007

Systematic Reviews and Meta-analysis

If gambling treatment was evidence based, what would it look like?

Workshop: Cochrane Rehabilitation 05th May Trusted evidence. Informed decisions. Better health.

The Sinclair Method (TSM) for the Treatment of Alcoholism. Clinical Research Findings and Best Protocol for Success Updated 2014

ADHD and Substance Use Disorders: An Intoxicating Combination

Chapter 6 Psychoeducation for depression, anxiety and psychological distress: a meta-analysis

Comorbid substance use disorders and mental health disorders among New Zealand prisoners. Ian Garrett Regional Director Practice Delivery

Primary Care Smoking Cessation. GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco

A systematic review of the efficacy and safety of fluoridation

Clinical Evidence. A BMJ database of the very best evidence for effective health care

Are Anti depressants Effective in the Treatment of Depressed Patients Who Do Not Seek Psychotherapy?

NeuRA Obsessive-compulsive disorders October 2017

Practical Interventions for Co-occurring Disorders: Dissemination from Efficacy and Effectiveness Studies

Bipolar Disorder Clinical Practice Guideline Summary for Primary Care

Chapter 11: SF-36 Health Status Questionnaire: Health Risk Behaviours, Specific Conditions and Health Service Utilisation

The Role of Occupational Performance in Prediction of Drug and Alcohol Abstinence in a Substance Abuse Population

Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women

New Zealanders alcohol consumption patterns across the lifespan

Summary. General introduction

Attention Deficit Hyperactivity Disorder

Alcohol use in advanced age: Findings from LiLACS NZ

Study protocol v. 1.0 Systematic review of the Sequential Organ Failure Assessment score as a surrogate endpoint in randomized controlled trials

Management of physical health conditions in adults with severe mental disorders

Alcohol Interventions: NICE guidelines and beyond. Professor Colin Drummond

What does the term Addiction - instead of Pathological Gambling - do for us and the sufferers?

Persistent Insomnia, Abstinence, and Moderate Drinking in Alcohol-Dependent Individuals

Overview of Adolescent Substance Abuse & Treatment

An Evaluation of the Effectiveness of the Lidcombe Program of Early Stuttering Intervention Mark A. Jones

Systematic Review Search Strategy

OXLEAS NHS FOUNDATION TRUST RESEARCH PROPOSAL

The Intersection of Post-Traumatic Stress and Substance Use Disorders. Implications for an emerging integrated treatment approach

Effective Treatments for Tobacco Dependence

Specialty substance use disorder services following brief alcohol intervention: a meta-analysis of randomized controlled trials

Method. NeuRA Biofeedback May 2016

Key Messages. Around 20% of children and adolescents are estimated to have mental health disorders or problems

Problem gambling and family violence: findings from a population representative community study

Clinical Epidemiology for the uninitiated

Technology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta325

Results. NeuRA Mindfulness and acceptance therapies August 2018

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders

A pilot randomised controlled trial of varenicline versus oral naltrexone for the treatment of alcohol dependence. Background 1

Cannabis Use Disorders: Using Evidenced Based Interventions to Engage Students in Reducing Harmful Cannabis Use or Enter Recovery

GLOSSARY OF GENERAL TERMS

HREGION THE TREATMENT AND RESEARCH INTEGRATED MODEL,TRIM. - How to make the most of your clinical data in a refugee health setting

IPAP PTSD Algorithm -- Addenda

Targeting cognitive dysfunction: Metacognitive Therapy for depression

Psychological therapies for people with dementia who have associated depression [New 2015].

SUBSTANCE ABUSE A Quick Reference Handout by Lindsey Long

Women s Program PRINCETON HAMILTON NORTH BRUNSWICK MOORESTOWN EATONTOWN. Partial Hospital Intensive Outpatient

Pharmacotherapy for Tobacco Dependence Treatment

DEPRESSION AFTER STROKE

Problem solving therapy

Observational the researcher collects information on attributes or measurements of interest but DOES NOT influence the results.

ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH

PATHOLOGICAL GAMBLING: NEUROBIOLOGY

THE NALTREXONE CHALLENGE

Module 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town

Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist.

What makes us ill?

The prevalence and care of mental disorders in Counties Manukau District Health Board from linked health data February 2009

CANDIS. A Marijuana Treatment Program for Youth and Adults SCOPE AND SEQUENCE. An Evidence-Based Program from

10 INDEX Acknowledgements, i

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

Technical Whitepaper

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

Biological Addictions Treatment. Psychology 470. Many Types of Approaches

Results. NeuRA Hypnosis June 2016

Clinical Use of Ketamine in Psychiatry

Protocol Sistematic Review

Mood Disorders for Care Coordinators

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

The Relationship between the Attachment Patterns and the Coping Skills with Drug Abuse

Investigation of HAZARDOUS DRINKING. 2 November 2010 best tests

Evidence profile. Brief Structured Psychological treatment.doc. Background on the scoping question

Dr. Meldon Kahan. Women s College Hospital. with PIA LAW

The age of feeling in-between : Factors that influence emerging adult outcomes during and after residential substance use disorder treatment

The role of behavioral interventions in buprenorphine treatment of opioid use disorders

Comorbidity With Substance Abuse P a g e 1

9/22/2015. Timothy W. Lineberry, MD Chief Medical Officer Greater Green Bay Aurora Health Care

National Autism Unit

Aiming for recovery for patients with severe or persistent depression a view from secondary care. Chrisvan Koen

Transcription:

Treating alcoholrelated depression James Foulds Senior Lecturer National Addiction Centre Christchurch, NZ

Overview of talk Epidemiology and etiology of alcoholrelated comorbidity Alcohol-related depression in clinical samples Evidence Systematic review and meta-analysis The TEAM study

Scott, KM et al 2006. Mental disorder comorbidity in Te Rau Hinengaro (NZ Mental Health Survey)

Alcohol and psychological distress: the J-shaped curve Percent with high distress Heavy drinkers Abstainers Moderate drinkers

percent 40 Percent with high psychological distress, by AUDIT score category 35 30 25 20 15 10 5 0 0 1 2-3 4-5 6-7 8-9 10-14 15-19 20+ AUDIT score Source: NZ Health Survey 06/07

Adamson et al, 2006. Co-existing disorders in a New Zealand Outpatient Alcohol and other Drug Clinical Population

Correlates of depressive comorbidity in substance use disorder samples service utilisation relapse disability suicide risk

Plausible mechanisms of association Common underlying cause, eg genes & early environment Alcohol causes mental illness, either via direct pharmacological effect or via life problems Mental illness promotes drinking, eg as a maladaptive coping strategy Bidirectional causation

Does alcohol causes depression? Probably, but demonstrating this conclusively is ethically difficult Experimental studies in late 1960s showed heavy drinking increased levels of anxiety and depression More circumstantial evidence from multiple other lines of research, eg cohort studies (not discussed today)

Does depression lead to drinking? Sometimes, but usually not Some evidence for motivational model of alcohol use (people drink to enhance positive affect or reduce negative affect) However, most patients with major depression if anything reduce rather than increase their alcohol use

Summary The causal relationship between alcohol and depression is complex varies between patients probably varies within patients over time is difficult to be certain about for any individual patient

Independent vs substance-induced depression Independent= depression present before onset of heavy drinking, or present during abstinence Otherwise= substance induced This typology widely believed to be valid and useful (eg Schuckit 2007; Pettinati 2013)

Research questions: How much does depression improve during treatment? What is the effect of antidepressants? What predicts depression outcomes? Does it matter if depression is categorised as independent or substance-induced?

Methods 1. Systematic review and meta-analysis: J Foulds, S Adamson, R Mulder, J Williman, J Boden 2. Treatment Evaluation of Alcohol and Mood (TEAM) study: S Adamson, D Sellman, J Foulds, L Nixon, G Cape et al

Meta-analysis Study 2 effect Study 1 effect Study 3 effect Overall effect

Define the research question and write a protocol Conduct literature search (preferably 2 independent authors) Extract data from studies Analyse data using meta-analysis model Summarise and interpret data

Inclusion criteria Studies were chosen according to the following criteria: 1. Studies with longitudinal data on alcohol use and depression over 8+ weeks in treatmentseeking populations 2. Subjects had a currently active alcohol use disorder 3. Mean baseline depression score 10 on the 17-item Hamilton Depression Rating Scale (or equivalent)

Search strategy MEDLINE, Embase and Cochrane databases plus reference lists from review articles in the field and the reference lists of studies in the final sample Search items were alcohol drinking; alcoholinduced disorder; alcohol-related disorder; alcoholics; alcoholism AND depression; antidepressive agents. English-language publications on subjects aged 18+ from 1980 onwards were considered.

Findings 22 studies identified, 11 included in metaanalysis Most studies were in mild-moderately depressed subjects Most studies were pharmacotherapy trials of antidepressants

Understanding effect sizes Question is not is this difference statistically significant (p value) Rather, how large is the group difference Effect size is a critically important concept when interpreting literature on treatments Many difference types of effect sizes (r value; standardised mean difference; odds ratio etc)

mean difference n σ 0 2 4 6 8 10 12 14 16 Daily alcohol consumption

Standardised mean difference

Change in depression with treatment

What is an effect size of 2? Depression score reduced by 2 standard deviations on average Equates to a 10 to 15 point reduction in Hamilton score A large effect ie moderate depression -> mild depressive symptoms

Independent vs substance-induced similar improvement in depression regardless of whether independent, substance-induced or undifferentiated depression no evidence reduced drinking benefits substance-induced depression more (probably benefits all patients) however the quality of evidence on substance-induced depression was low

Antidepressant effect

Meta-analysis summary Large early improvement in depression regardless of depression type and treatment provided Improvement reaches a plateau within 6-12 weeks Significant minority of patients remains depressed Antidepressants at best have very modest effect Evidence for antidepressants strongest in independent depression Reduced drinking probably helps depression

The TEAM study Multi-site RCT conducted in NZ (Prof Doug Sellman, Assoc Prof Simon Adamson principal investigators) n=138 Naltrexone + citalopram / placebo 12 week active treatment phase + naturalistic follow up at 24 at 64 weeks All subjects received manualised clinical case management Subjects not abstinent at baseline (in keeping with standard outpatient practice)

Baseline sample characteristics Total Sample Citalopram n=73 Placebo n=65 p Age 43.6 (9.1) 44.6 (8.6) 42.4 (9.5).148 Female 59.4% 60.3% 58.5%.829 NZ Maori 17.4% 15.1% 20.0%.446 Employed 55.1% 53.4% 56.9%.680 Antidepressants 76.1% 80.8% 70.8%.167 Independent depression 76.1% 69.9% 83.1%.069 Major Depressive Disorder, onset age 24.3 (11.4) 26.3 (12.4) 22.2 (9.9).035 MADRS 31.0 (5.8) 31.3 (5.6) 30.6 (6.0).434 Percent Days Abstinent (PDA) 25.8 (27.4) 25.5 (28.4) 26.1 (26.4).906 Percent Days Heavy Drinking (PDH) 58.9 (33.6) 60.7 (34.9) 56.8 (32.2).505 Drinks Per Drinking Day (DDD) 14.3 (8.0) 14.3 (7.4) 14.4 (8.6).909

Effect of citalopram

MADRS score Effect of depression type 35 30 25 20 15 Independent Substance-induced 10 5 0 0 3 6 9 12 15 18 21 24 Week number Figure 1:MADRS score from baseline to week 24, for subjects with independent and substance-induced depression; p value=.004 for the overall difference between groups in repeated measures analysis. Estimates of MADRS score at timepoints from week 3 to week 24 are least squares means from linear mixed models including time as a categorical predictor. Standardised mean difference 0.68 for group difference across all timepoints (excluding baseline) and 0.54 for group difference at week 24.

Percentage of days abstinent Change in percent days abstinent 90 80 70 60 50 40 30 20 10 Independent Substance-induced 0 0 3 6 9 12 15 18 21 24 Week number

Relationship between change in depression and change in drinking Drinking outcome n % of sample No improvement in percent days abstinent 22 15.9 41.0 (5.8) Percent improvement in MADRS from baseline to 24 weeks % (SE) Increased days abstinent; still drinking >50% of days 27 19.6 62.0 (4.4) Increased days abstinent, drinking <50% of days Total abstinence last 3 weeks of study 59 42.8 77.6 (5.0) 30 21.7 73.3 (3.9) ANOVA for group differences: F=9.4, p<0.001

MADRS score MADRS score Personality and depression outcome Self-directedness Harm avoidance 35 25 30 20 25 20 15 10 5 quartile 1 quartile 2 quartile 3 quartile 4 15 10 5 q1 q2 q3 q4 0 0 3 6 9 12 15 18 21 24 Week number 0 3 6 9 12 15 18 21 24 Week number

TEAM study summary No effect of citalopram in this sample Rapid large improvement in depression and drinking Subjects who did not increase their percentage of abstinent days had much worse depression outcomes Substance-induced depression patients had more change in both drinking and depression Personality traits influence depression outcome

Other drug classes No evidence naltrexone helps or worsens depression Little evidence for other classes of drugs eg lithium

Psychological treatments Overall: limited evidence available overall; however some evidence for CBT and integrated motivational interventions targeting both drinking and mood

Summary Antidepressants relatively ineffective in alcohol use disorders Standard treatment produce rapid, large improvements in depression Probably not very useful to determine whether depression is alcohol-induced Reduced drinking associated with better depression outcomes; this may be partly causal Specific psychological therapies may be useful but limited evidence Personality predicts depression outcome

Acknowledgements Thank you to collaborators / coauthors: Simon Adamson Doug Sellman Roger Mulder Joe Boden Elisabeth Wells Thanks to TEAM study participants, research clinicians and Medical Officers